TRAX Reports Positive Celiac Study Results; MIRM Meets Phase 3 Endpoint
Premarket mover roundup also includes TRMD’s full-year guidance upgrade, talk of advanced sale talks involving CCC, and BMY’s positive interim Phase 3 ACTION-1 results. The source also cites analyst upgrades for CRM, BIIB and FSLR, plus a DHT business update.
Among large-cap premarket movers, TRAX rose +25% after announcing positive top-line results for ANB033 in a gluten-challenge study in celiac disease. MIRM gained +5% after meeting the primary endpoint in the Phase 3 EXPAND study of LIVMARLI® (maralixibat). CCC advanced +11% amid talk of advanced sale discussions with GTCR and Elliott Investment. 5% on a business update.
CRM gained +4% after a BUY upgrade at BAC, and BIIB rose +4% following an OVERWEIGHT upgrade at JPM. 5% after a BUY upgrade at Truist. BMY added +3% after positive topline results from the interim analysis of Phase 3 ACTION-1 for RYZ101.